Navigation Links
Breast Cancer Treatment Reduced From Six Weeks To Five Days.

A new therapy to treat breast cancer reduces the radiation time from six weeks to five days. This is very useful for the patients as it is less convenient. Doctors// can point the radiation source at the tumor killing the cancer cells.

The study compares the usefulness of the new therapy over the conventional six-week treatment. They are also in the process of analyzing the suitable subjects for this therapy.

But the Canadians are working on a new therapy for breast cancer, which reduces the treatment time to just 24 hours.

This can be possible by implanting radiation seeds permanently in the patient’s breast thereby facilitating the destruction of cancer cells. This method helps the patient o continue with their normal routine.

This new method of treatment of breast cancer is called partial-breast radiation therapy.

But experts have their reservations and tell the patients who opt or the new therapy to enroll them in the study wherein they are testing the feasibility of the new approach.

But Dr. Norman Coleman working at the national cancer institute questions the researchers the effectiveness of the new therapy as this can work well in few patients and only very few patients are followed to ensure that this is therapy works better than the conventional one.

Dr. Frank Vicini of William Beaumont Hospital in Royal Oak, Mich., who initiated the five-day approach and is currently presiding the new NCI study.

He said that around 200,000 American (70%) suffering from breast cancer patients opt for a lumpectomy (removal of the tumor) and not the removal of the entire breast.

In addition to lumpectomy radiation helps in the treatment of early-stage breast cancer.

Partial-breast radiation is a very useful tehnique in the prevention of recurrence of breast cancer and also reduces the side effects faced during the conventional methods.


'"/>




Page: 1

Related medicine news :

1. Consensus on "Combination Therapy" for Breast Cancer
2. Breast cancer treatment to be determined by gene test
3. Breast Feeding prevents obesity later on in life
4. Breast milk is essential
5. Breast Cancer Surgery Causes Psychological problems
6. Breast cancer evidence
7. Letrozole Beats Tamoxifen in Breast Cancer Therapy
8. Breast screening among diabetic women
9. Breast feeding can alter hormones
10. Diet, Sunlight connected to Breast Cancer Risk
11. Additional Radiotheraphy for Breast Cancer

Post Your Comments:
(Date:11/30/2009)... Tenn., Nov. 30 During this time o...holidays. For a loved one with Alzheimer,s disease...ends oftentimes struggle with appropriate gift ite...ading providers of senior living residences in the..., offers these suggestions. ,, A listening dev...
(Date:11/30/2009)...se Control and Prevention estimate that well over ...ed with HIV/AIDS. New research from North Carolina...d are minorities and do not have health insurance,...o facilitate education and prevention efforts in m...ch, which analyzed 90,000 HIV patient hospital vis...
(Date:11/30/2009)...thor of "My Two-Year Old Eats Octopus," ...to eat everything. , (PRW... in your house? Do you find yourself acting as a ...ine videos – one focusing on packing lunches...rs for real-life parents’ questions – ...
(Date:11/30/2009)...Colo., Nov. 30 Baxa Corporation is... what "culture of safety" means in today,s pharmac... "Creating a Culture of Safety in Pharmacy ," fea...ssing their experiences with culture of safety, wh...cy and the role of technology in enabling or inhib...
(Date:11/30/2009)..., Nov. 30 Stryker Corpor...agreement to acquire privately held Ascent Health...ocessing and remanufacturing of medical devices in... Stryker will acquire Ascent Healthcare Solutions ...losing is conditioned on the expiration or termina...
Breaking Medicine News(10 mins):Health News:Gift Ideas for Loved Ones with Alzheimer's/Dementia 2Health News:Research highlights need for national HIV strategy 2Health News:New Videos Help Parents of Picky Eaters 2Health News:New Videos Help Parents of Picky Eaters 3Health News:Baxa to Sponsor ASHP Midday Symposium: Creating a Culture of Safety in Pharmacy, A Panel Discussion on Lessons Learned 2Health News:Baxa to Sponsor ASHP Midday Symposium: Creating a Culture of Safety in Pharmacy, A Panel Discussion on Lessons Learned 3Health News:Stryker Announces Definitive Agreement To Acquire Ascent Healthcare Solutions 2Health News:Stryker Announces Definitive Agreement To Acquire Ascent Healthcare Solutions 3
...) today announced third quarter and nine months re...ber 31, 2007, Hawkins reported sales,increased 30....ame period a,year ago. Net income for the quarter ...For the nine months ended December 31, 2007, Hawki...
...(Nasdaq: MLAB ) today announced that its Board of...ividend of ten cents per share of common,stock, pa...at the close of,business on February 25, 2008., M...ews release contains forward-looking statements wh...
... (both children and adults) when given gadolinium ... pre-medicated with corticosteroids and antihistam...earchers at the University of Michigan Health Syst...t agents, said Jonathan R. Dillman, MD, lead autho...
... Spending Cuts, ALEXANDRIA, Va., Feb. 8 Presiden...th programs vital to the future of,health and heal...on cut in,Medicaid, the nation,s single largest pa...end on, ranging from poison,control hotlines to fu...
....uk ), the,online ,front door, to the NHS, launche...sense of the stories appearing in the news about m...oices,( http://www.nhs.uk/News/Pages/NewsIndex.asp...g of the science. It,also provides an authoritativ...
...nger is suppressed , , FRIDAY, Feb. 8 (Hea...arriage is communication, and new research now not...tudy of Midwestern couples finds that those who fe...orst thing to do is to keep it in, not talk about ...
Other Medicine News:Health News:Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results 2Health News:Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results 3Health News:Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results 4Health News:Allergic-like reactions occur in premedicated patients 2Health News:Bush Budget Cuts Federal Health Programs Vital to the Health of All Children 2Health News:Bush Budget Cuts Federal Health Programs Vital to the Health of All Children 3Health News:Mutual Resentment in Marriage Can Be Deadly 2Health News:Mutual Resentment in Marriage Can Be Deadly 3
(Date:11/30/2009).... 30 Cytokine PharmaSciences, Inc.... of CPSI-2364, its orally active, small-molecule i...pro-inflammatory cytokines. Results of the safety... volunteers confirm the safety of this compound in... subjects completed the study, including those rec...
(Date:11/30/2009)...PRNewswire/ -- The Simmons law firm,s Trent Miracl...ing thousands of women that were seriously injured...rol pill manufactured and marketed by Bayer Pharma...istrict Litigation has ordered that all federal Ya...idated and centralized for pretrial litigation in ...
(Date:11/30/2009)... 30 According to Millennium Resear...chnology market intelligence, the nearly $1.2 bill...most 5% over 2008 as patients chose to delay or fo... The market will, however, begin recovery in 2010,...ion growth rates of over 15%. MRG,s facial injecta...
Breaking Medicine Technology:Cytokine PharmaSciences Completes Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364 2Simmons Firm's Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer 2Facial Injectables Emerge From the Recession 2Facial Injectables Emerge From the Recession 3Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 1Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 2Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 3Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 4Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 5Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 6Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 7Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 1Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 2Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 3Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 4Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 1Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 2Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 3Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 4
...MELBOURNE, Australia, Feb. 11 Phosphagenics,Limit...PGNY) and Nestle,Nutrition (Nestle) today announce... establish the efficacy of Phosphagenics, Phospha ...vancing at three sites in Adelaide,Australia., Ba...ants, the,double-blind phase 2 trial, which is ful...
...BOULDER, Colo., and MONTREAL, Feb. 11 ,Pharmion (N...y announced that,the European Medicines Agency (EM...CD0103, a histone deacetylase (HDAC) inhibitor, as...acute myelogenous leukemia in the,European Union (...duct be,intended for the treatment of life-threate...
Other Medicine Technology:Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 2Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 3Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 4Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 2Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 3Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 4
VascoScrew E 8/60 M
VascoScrew P 6/60 M
VascoScrew E 6/60 S
VascoScrew E 5/60 PU M
Medicine Products: